Phalguni Deswal

The company has discontinued the Phase I/II trial of its only clinical candidate due to a potential “unfavourable risk-benefit profile”.

Veeva’s VP of global medical, Christoph Bug, emphasises the importance of scientific exchange between clinical experts and pharmaceutical companies.

The company’s VP of digital excellence explains how the Japanese biotech engages with data and uses it to inform decision making.

Medtronic and Fortimedix Surgical did not disclose the financial details of the acquisition. Image credit: JHVEPhoto / Shutterstock.

The Phase III STELLAR trial evaluated the eflornithine and lomustine combination in patients with IDH mutant astrocytoma.

The company also stopped the long-term extension study for the AL002 and laid off 17% of its employees.

The Norse Eight trial was part of the data requested by the FDA after the agency rejected the BLA for the company's Lytenava last year.

The correction was issued following the FDA's letter citing the potential risk of exposure to toxic compounds when using haemodialysis and peritoneal dialysis systems.

An open- label Phase III trial showed that participants using Zepbound saw 47% greater relative weight loss compared to Wegovy.

Veeva Europe president Chris Moore talks about the company's new genAI-powered releases and its move from Salesforce to a proprietary CRM platform.